Related Experiment Video
Updated: Jul 12, 2025

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
Published on: July 5, 2022
Serum cystatin C for risk stratification of prediabetes and diabetes populations
Kun Xiong1, Shiran Zhang1, Pingting Zhong1
1State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, 510000, Guangdong Province, China; Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, 510000, Guangdong Province, China; Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, 510000, Guangdong Province, China.
Insights
Serum cystatin C levels predict higher risks of mortality and vascular issues in individuals with diabetes and prediabetes. This biomarker improves risk assessment for these conditions.
Area of Science:
- Endocrinology
- Nephrology
- Cardiology
- Ophthalmology
Background:
- The link between serum cystatin C and vascular outcomes in diabetes is not fully understood, and it remains unclear in prediabetes.
- This study aimed to determine if serum cystatin C levels can predict the future risk of mortality and vascular complications in individuals with prediabetes and diabetes.
Purpose of the Study:
- To investigate the predictive value of serum cystatin C levels for mortality and vascular outcomes in prediabetes and diabetes.
- To assess the impact of cystatin C on retinal microvascular changes and neural layer degeneration in diabetes.
Main Methods:
- Utilized UK Biobank data from 85,371 participants with prediabetes/diabetes and baseline cystatin C levels, with a 14-year follow-up.
- Employed Cox hazards models to analyze associations between cystatin C, mortality (all-cause, cause-specific), and vascular outcomes (MI, stroke, ESRD, DR).
- Incorporated data from 1136 diabetes subjects in the Guangzhou Diabetic Eye Study (GDES) using SS-OCT and OCTA to examine in vivo retinal changes.
Main Results:
- The highest quartile of cystatin C was associated with significantly increased risks for all-cause, cardiovascular, cancer, and other-cause mortality.
- Elevated cystatin C levels correlated with higher risks of myocardial infarction, stroke, end-stage renal disease, and diabetic retinopathy.
- Adding cystatin C to conventional models significantly improved risk prediction (C-statistic) for various mortality and vascular outcomes. GDES analysis showed increased cystatin C linked to retinal neural layer thinning and microvascular rarefaction.
Conclusions:
- Serum cystatin C serves as a valuable biomarker for refining risk stratification in patients with prediabetes or diabetes.
- Elevated cystatin C levels are associated with increased mortality and a spectrum of vascular complications, including specific ocular changes.
Background:
The association between serum cystatin C level and vascular outcomes has not been fully elucidated in diabetes and is unclear in prediabetes. We aim to evaluate whether cystatin C level predicts future risk for mortality and vascular outcomes in prediabetes and diabetes.
Methods:
A total of 85,371 participants with prediabetes and diabetes, and available baseline cystatin C in the UK biobank were included with a 14-year follow-up. Cox hazards models were used to calculate the associations between cystatin C level, mortality (all-cause, cause-specfic mortality) and vascular outcomes (myocardial infarction [MI], stroke, end-stage renal disease [ESRD] and diabetic retinopathy [DR]). The 1136 diabetes subjects in Guangzhou Diabetic Eye Study (GDES) were included for examing the impact of cystatin C on in vivo retinal degeneration and microvascular changes by using SS-OCT and OCTA.
Results:
The highest cystatin C quartile had increased risks of all-cause (hazard ratio [HR], 2.02; 95% confidence interval [CI] 1.86-2.19), cardiovascular (HR, 2.29; 95% CI 1.97-2.67), cancer (HR, 1.86; 95% CI 1.65-2.10) and other-cause mortality (HR, 2.24; 95% CI 1.90-2.64), MI (HR, 1.40; 95% CI 1.26-1.55), stroke (HR, 1.88; 95% CI, 1.57-2.26), ESRD (HR, 7.33; 95% CI, 5.02-10.71), DR (HR, 1.17; 95% CI 1.03-1.32) than those in the lowest quartile. Adding cystatin C to the conventional model improved C-statistic for all-cause (0.699-0.724), cardiovascular (0.762-0.789), cancer (0.661-0.674) and other-cause mortality (0.675-0.715), MI (0.748-0.750), stroke (0.712-0.718), and ESRD (0.808-0.827). The GDES analysis identified a strong association between increased cystatin C levels and diminished retinal neural layers, as well as microvascular rarefaction in both macular and optic disc regions (all P < 0.05).
Conclusions:
Serum cystatin C refines the risk stratification for mortality and vascular outcomes among patients with prediabetes or diabetes.
Related Concept Videos
Serum Studies: Renal Function Tests
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Nephrotic Syndrome II : Assessment and Medical Management
Diabetes: Symptoms, Diagnosis, and Complications
Chronic Kidney Disease I: Introduction
Diabetes Mellitus: Type 2 and Gestational

